New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:20 EDTCNATConatus Pharmaceuticals price target lowered to $14 from $16 at Stifel
Stifel cut its price target on Conatus as the firm thinks the extension of P2b ACLF data timelines due to slower than expected enrollment is negative. However, the firm keeps a Buy rating on the stock.
News For CNAT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for CNAT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use